Results 81 to 90 of about 149 (148)

Immune Checkpoint Inhibitors and Cardiovascular Adverse Events

ESC Heart Failure, EarlyView.
Abstract In the last years, we assisted to a tremendous increase in therapeutic options for the management of cancers, with immunotherapy at the forefront of this innovation. Immune checkpoint inhibitors (ICIs) have been developed to enhance the activity of the immune system against cancer cells (1) and the number of approvals for ICIs has rapidly ...
Maria Luisa De Perna, Elia Rigamonti, Raffaele Zannoni, Vittoria Espeli, Giorgio Moschovitis   +4 more
wiley   +1 more source

Plasma metabolomics identifies signatures that distinguish heart failure with reduced and preserved ejection fraction

ESC Heart Failure, EarlyView.
Abstract Aims Two general phenotypes of heart failure (HF) are recognized: HF with reduced ejection fraction (HFrEF) and with preserved EF (HFpEF). To develop phenotype‐specific approaches to treatment, distinguishing biomarkers are needed. The goal of this study was to utilize quantitative metabolomics on a large, diverse population to replicate and ...
Fawaz Naeem, Teresa C. Leone, Christopher Petucci, Clarissa Shoffler, Ravindra C. Kodihalli, Tiffany Hidalgo, Cheryl Tow‐Keogh, Jessica Mancuso, Iphigenia Tzameli, Donald Bennett, John D. Groarke, Rachel J. Roth Flach, Daniel J. Rader, Daniel P. Kelly   +13 more
wiley   +1 more source

Early prescription of quadruple therapy in acute decompensated heart failure with reduced ejection fraction: A propensity score‐matched analysis

ESC Heart Failure, EarlyView.
This propensity score‐matched analysis of 2051 acute decompensated heart failure patients from the ICARUS registry compared 898 patients who received early quadruple guideline‐directed medical therapy (within 48 h of admission) to 1153 matched controls.
Luis E. Echeverría, Lyda Z. Rojas, Angie Yarlady Serrano‐García, Daniel Botero, Karen Andrea García‐Rueda, Ángela Torres‐Bustamante, Diana Ivonne Cañón‐Gómez, Juan Sebastián Salcedo, Alexandra Hurtado‐Ortiz, Jaime A. Rodríguez, Sergio A. Gómez‐Ochoa   +10 more
wiley   +1 more source

BUN‐to‐ALB ratio as an effective predictor of 30 day mortality in ADHF patients in eastern China

ESC Heart Failure, EarlyView.
Abstract Aims The blood urea nitrogen‐to‐albumin ratio (BAR) is considered a potential indicator for assessing the poor prognosis of heart failure (HF). However, its prognostic value for Chinese patients with acute decompensated HF (ADHF) remains unclear.
Xin Huang, Chao Wang, Shiming He, Guoan Jian, Kun Jiang, Zihao Lu, Guotai Sheng, Yang Zou, Guobo Xie   +8 more
wiley   +1 more source

Exploring heart failure prevalence and dimensions: A comprehensive NT‐proBNP study in high‐risk primary care patients

ESC Heart Failure, EarlyView.
The diagnostic pathway of high‐risk primary care patients through NT‐proBNP. Abstract Introduction Early detection of heart failure (HF), particularly in asymptomatic individuals, is essential for timely intervention. This study aimed to determine the prevalence of HF among high‐risk individuals in primary care using N‐terminal probrain natriuretic ...
Ahmet Celik, Emrah Yesil, Unal Kılıç, Gizem Akcay Ozyurt, Selman Aytimur, Mustafa Demir, Huseyin Naci Eker, Ayse Siddika Col, Cemil Ilker Altiparmak, Mustafa Ergen, Selen Bozkaya, Ismail Sefa Okyay, Ibrahim Ethem Kerem, Kiristin Marina Arap, Melike Yirtar, Deniz Korkmaz, Ali Kırdağ, Ismail Turkay Ozcan   +17 more
wiley   +1 more source

Identification of serum C4BPA as a potential diagnostic marker of right ventricular remodelling via proteomic analysis

ESC Heart Failure, EarlyView.
Abstract Aims Right ventricular (RV) remodelling, a progressive condition characterized by maladaptive cardiac structural and functional changes, primarily results from prolonged pressure overload in patients with pulmonary hypertension (PH). Accurate, universal and easy‐to‐use biomarkers for assessing the severity of RV remodelling are lacking.
Xuenan Wang, Cheng Yu, Meiling Li, Huiling Cai, Yongjian Yang, Cong Lan   +5 more
wiley   +1 more source

Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence

ESC Heart Failure, EarlyView.
Abstract Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors represent one of the main cornerstones of heart failure treatment. Nevertheless, while the cardiovascular beneficial effects of these drugs have been clearly demonstrated by several clinical trials, in clinical practice, it remains challenging to identify the appropriate timing to start SGLT2 ...
Ruggero Mazzotta, Manuel Garofalo, Samuele Salvi, Matteo Orlandi, Gianluca Marcaccini, Pietro Susini, Luca Checchi, Alberto Palazzuoli, Carlo Di Mario, Maurizio Pieroni, Matteo Beltrami   +10 more
wiley   +1 more source

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure, EarlyView.
Abstract Background Sodium glucose co‐transporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA) reduce heart failure (HF) events in patients with heart failure and mildly reduced or preserved ejection fraction (HFmr/pEF). The randomized comparison of SGLT2i/MRA combination versus SGLT2i or MRA alone requires further testing in ...
João Pedro Ferreira, Francisco Vasques‐Nóvoa, Francisca Saraiva, Ana C. Oliveira, Jorge Almeida, Ana Beatriz Batista, Arsénio Barbosa, Ana Filipa Ferreira, Cátia Costa, Diogo Santos‐Ferreira, Fernando Friões, Cândida Goncalves, João Tiago Guimarães, Marta Leite, Pedro Marques, Joana Mascarenhas, Maria Inês Matos, Catarina Pereira, Pedro Rodrigues, Abhinav Sharma, Gualter Silva, Inês Pereira‐Sousa, Carla Sousa, Faiez Zannad, Joana Pimenta, Ricardo Fontes‐Carvalho, Adelino Leite‐Moreira   +26 more
wiley   +1 more source

Plasma volume status predicting clinical outcomes in patients undergoing transcatheter edge‐to‐edge mitral valve repair

ESC Heart Failure, EarlyView.
Abstract Aims Plasma volume status (PVS) is recognized as a marker of systemic congestion, but its clinical utility in patients with mitral regurgitation (MR) undergoing transcatheter edge‐to‐edge mitral valve repair (M‐TEER) has not been well established. This study aimed to evaluate the prognostic significance of PVS in these patients.
Ai Kagase, Masanori Yamamoto, Takahiro Tokuda, Ryotaku Kawahata, Hiroto Nishio, Tetsuro Shimura, Ryo Yamaguchi, Mitsuru Sago, Yuki Izumi, Mike Saji, Masahiko Asami, Yusuke Enta, Masaki Nakashima, Shinichi Shirai, Masaki Izumo, Shingo Mizuno, Yusuke Watanabe, Makoto Amaki, Kazuhisa Kodama, Junichi Yamaguchi, Toru Naganuma, Hiroki Bouta, Yohei Ohno, Masahiro Yamawaki, Hiroshi Ueno, Kazuki Mizutani, Daisuke Hachinohe, Toshiaki Otsuka, Shunsuke Kubo, Kentaro Hayashida, OCEAN‐Mitral Investigators   +30 more
wiley   +1 more source

Dapagliflozin effect on functional mitral regurgitation and myocardial remodelling: The DEFORM trial

ESC Heart Failure, EarlyView.
Abstract Aims Functional mitral regurgitation (FMR) is associated with adverse outcomes in patients with heart failure, and current guideline‐directed medical therapy (GDMT) offers limited efficacy in managing FMR. This study aims to evaluate the therapeutic impact of the sodium‐glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin in patients with ...
Zhuoshan Huang, Rui Fan, Shaozhao Zhang, Junlin Zhong, Yiquan Huang, Peihan Xie, Shanshan Yin, Xiaomin Ye, Xinghao Xu, Rihua Huang, Zhenyu Xiong, Yue Guo, Menghui Liu, Yifen Lin, Suhua Li, Xiaoxian Qian, Jinlai Liu, Xiaodong Zhuang, Xinxue Liao   +18 more
wiley   +1 more source